Healthcare -
Biotechnology - NASDAQ - US
$ 5.7
0.885 %
$ 618 M
Market Cap
-4.75
P/E
1. INTRINSIC VALUE
Balance Sheet
Tango Therapeutics, Inc.
| Current Assets | 266 M |
| Cash & Short-Term Investments | 258 M |
| Receivables | 0 |
| Other Current Assets | 8.43 M |
| Non-Current Assets | 50.1 M |
| Long-Term Investments | 0 |
| PP&E | 47.6 M |
| Other Non-Current Assets | 2.57 M |
| Current Liabilities | 38.2 M |
| Accounts Payable | 1.6 M |
| Short-Term Debt | 2.45 M |
| Other Current Liabilities | 34.1 M |
| Non-Current Liabilities | 78.8 M |
| Long-Term Debt | 34 M |
| Other Non-Current Liabilities | 44.8 M |
EFFICIENCY
Earnings Waterfall
Tango Therapeutics, Inc.
| Revenue | 42.1 M |
| Cost Of Revenue | 0 |
| Gross Profit | 42.1 M |
| Operating Expenses | 188 M |
| Operating Income | -146 M |
| Other Expenses | -15.3 M |
| Net Income | -130 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Tango Therapeutics, Inc.
| Net Income | -130 M |
| Depreciation & Amortization | 2.5 M |
| Capital Expenditures | -754 K |
| Stock-Based Compensation | 28.9 M |
| Change in Working Capital | -31.7 M |
| Others | -31.4 M |
| Free Cash Flow | -132 M |
Wall Street Analysts Price Targets
Tango Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for TNGX of $15 , with forecasts ranging from
a
low of
$13 to a high of $18 .
TNGX Lowest Price Target
Wall Street Target
13 USD
128.07%
TNGX Average Price Target
Wall Street Target
15 USD
163.16%
TNGX Highest Price Target
Wall Street Target
18 USD
215.79%
4. DIVIDEND
ANALYSIS
TNGX does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Tango Therapeutics, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
143 K USD 4
6-9 MONTHS
28.6 M USD 2
9-12 MONTHS
24.4 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
74 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer.
globenewswire.com
- 1 week ago
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
Tango Therapeutics (TNGX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
zacks.com
- 2 weeks ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 10 at 3:20-3:55 PM ET.
globenewswire.com
- 1 month ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the TNG456 Phase 1/2 trial in patients with MTAP-deleted solid tumors, with a focus on glioblastoma (GBM). TNG456 is a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor.
globenewswire.com
- 1 month ago
Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.35 per share a year ago.
zacks.com
- 1 month ago
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2025, and provided business highlights. “Accumulating data continue to support TNG462 as the potential best-in-class PRMT5 inhibitor,” said Barbara Weber, M.D.
globenewswire.com
- 1 month ago
Tango Therapeutics, Inc. (TNGX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 2 months ago
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.
globenewswire.com
- 2 months ago
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.
globenewswire.com
- 3 months ago
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates
Tango Therapeutics, Inc. (TNGX) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.32 per share a year ago.
zacks.com
- 4 months ago
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio ® (abemaciclib) established – – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported financial results for the fourth quarter and full year ended December 31, 2024, and provided business highlights.
globenewswire.com
- 4 months ago
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the Guggenheim SMID Cap Biotechnology Conference on Wednesday, February 5, 2025 at 10:00 AM ET.
globenewswire.com
- 5 months ago
8. Profile
Summary
Tango Therapeutics, Inc. TNGX
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 618 M
Dividend Yield
0.00%
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Contact
100 Binney Street, Boston, MA, 02142
https://www.tangotx.com
IPO
Date
Sept. 3, 2020
Employees
155
Officers
Ms. Daniella Beckman CPA
Chief Financial Officer
Mr. Douglas J. Barry Esq., J.D.
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Julie Carretero
Chief Human Resources Officer
Dr. Adam S. Crystal M.D., Ph.D.
President of Research & Development
Dr. William G. Kaelin Jr., M.D.
Founder & Member of Scientific Advisory Board
Dr. Michael Palmieri Ph.D.
Head of Technical Operations
Mr. Jannik N. Andersen Ph.D.
Chief Scientific Officer
Ms. Elizabeth Pingpank Hickin
Vice President of IR & Corporate Communications
Dr. Barbara L. Weber M.D.
President, Chief Executive Officer & Director
Dr. Antoni Ribas M.D., Ph.D.
Founder & Member of Scientific Advisory Board